Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
GAITHERSBURG, Md., June 24, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 24, 2023 Category: Pharmaceuticals Source Type: clinical trials
A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults
Condition: Anthrax Interventions: Biological: BW-1010: 50 µg - sprayer - IN; Biological: BW-1010: 50 µg - pipette - IN; Biological: BW-1010: 100 µg - sprayer - IN; Biological: BW-1010: 100 µg - pipette - IN; Biological: Saline (Placebo) - sprayer - IN; Biological: Saline (Pl acebo) - pipette - IN; Biological: BioThrax (positive control) - SC Sponsors: BlueWillow Biologics; Porton Biopharma Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2019 Category: Research Source Type: clinical trials
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study
Condition: Anthrax Interventions: Drug: Ciprofloxacin 500Mg Tablet; Drug: Doxycycline 100Mg Tablet; Biological: AV7909 Sponsors: Emergent Product Development Gaithersburg, Inc.; Biomedical Advanced Research and Development Authority Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 26, 2019 Category: Research Source Type: clinical trials
